[go: up one dir, main page]

JO3639B1 - صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد - Google Patents

صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد

Info

Publication number
JO3639B1
JO3639B1 JOP/2015/0161A JOP20150161A JO3639B1 JO 3639 B1 JO3639 B1 JO 3639B1 JO P20150161 A JOP20150161 A JO P20150161A JO 3639 B1 JO3639 B1 JO 3639B1
Authority
JO
Jordan
Prior art keywords
tetrafluoropropoxy
indol
fluoro
ethyl
polymorphic form
Prior art date
Application number
JOP/2015/0161A
Other languages
English (en)
Inventor
Birklund Andersen Kristine
Lopez De Diego Heidi
Harold Rock Michael
Dennis Therkelsen Frans
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3639(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of JO3639B1 publication Critical patent/JO3639B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بصورة متعددة الشكل جديدة من N-[2-(6-فلورو-1H-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد.
JOP/2015/0161A 2014-07-04 2015-07-01 صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد JO3639B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04

Publications (1)

Publication Number Publication Date
JO3639B1 true JO3639B1 (ar) 2020-08-27

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0161A JO3639B1 (ar) 2014-07-04 2015-07-01 صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد

Country Status (42)

Country Link
US (1) US10071963B2 (ar)
EP (1) EP3164385B1 (ar)
JP (2) JP6643330B2 (ar)
KR (1) KR102399374B1 (ar)
CN (3) CN112961094A (ar)
AP (1) AP2016009643A0 (ar)
AR (1) AR101109A1 (ar)
AU (1) AU2015282909B2 (ar)
CA (1) CA2951794C (ar)
CL (1) CL2017000002A1 (ar)
CO (1) CO2017000019A2 (ar)
CR (1) CR20160605A (ar)
CY (1) CY1124594T1 (ar)
DK (1) DK3164385T3 (ar)
DO (1) DOP2017000001A (ar)
EA (1) EA035894B1 (ar)
EC (1) ECSP17000222A (ar)
ES (1) ES2893619T3 (ar)
GE (2) GEAP202114363A (ar)
HR (1) HRP20211596T8 (ar)
HU (1) HUE056368T2 (ar)
IL (1) IL249428B (ar)
JO (1) JO3639B1 (ar)
LT (1) LT3164385T (ar)
MA (1) MA40345B1 (ar)
MX (1) MX377013B (ar)
MY (1) MY190715A (ar)
NZ (1) NZ727251A (ar)
PE (1) PE20170522A1 (ar)
PH (1) PH12016502477B1 (ar)
PL (1) PL3164385T3 (ar)
PT (1) PT3164385T (ar)
RS (1) RS62380B1 (ar)
RU (1) RU2016151637A (ar)
SG (1) SG11201610334XA (ar)
SI (1) SI3164385T1 (ar)
SM (1) SMT202100575T1 (ar)
SV (1) SV2016005353A (ar)
TN (1) TN2016000549A1 (ar)
TW (1) TWI665188B (ar)
UA (1) UA121547C2 (ar)
WO (1) WO2016001398A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305838B6 (cs) 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
PT3164385T (pt) 2021-10-07
SMT202100575T1 (it) 2021-11-12
EP3164385B1 (en) 2021-09-08
RU2016151637A (ru) 2018-08-08
ES2893619T3 (es) 2022-02-09
TN2016000549A1 (en) 2018-04-04
HUE056368T2 (hu) 2022-02-28
RS62380B1 (sr) 2021-10-29
MX2016016895A (es) 2017-04-27
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
PL3164385T3 (pl) 2021-12-20
JP2020059724A (ja) 2020-04-16
US20170152227A1 (en) 2017-06-01
BR112017000127A2 (pt) 2018-01-23
CY1124594T1 (el) 2022-07-22
CN106458889A (zh) 2017-02-22
CR20160605A (es) 2017-04-24
TWI665188B (zh) 2019-07-11
DK3164385T3 (da) 2021-10-11
PH12016502477A1 (en) 2017-04-10
IL249428B (en) 2019-10-31
AR101109A1 (es) 2016-11-23
NZ727251A (en) 2023-06-30
GEP20227368B (en) 2022-03-25
WO2016001398A1 (en) 2016-01-07
US10071963B2 (en) 2018-09-11
MA40345A (fr) 2021-04-28
MX377013B (es) 2025-03-07
TW201625525A (zh) 2016-07-16
CA2951794C (en) 2023-03-07
HRP20211596T8 (hr) 2022-03-04
JP6643330B2 (ja) 2020-02-12
AU2015282909B2 (en) 2019-02-07
UA121547C2 (uk) 2020-06-25
EA035894B1 (ru) 2020-08-27
DOP2017000001A (es) 2017-03-31
CN112961094A (zh) 2021-06-15
MY190715A (en) 2022-05-12
IL249428A0 (en) 2017-02-28
HRP20211596T1 (hr) 2022-01-07
PH12016502477B1 (en) 2017-04-10
JP2017519829A (ja) 2017-07-20
RU2016151637A3 (ar) 2019-01-28
SG11201610334XA (en) 2017-01-27
CO2017000019A2 (es) 2017-05-31
SV2016005353A (es) 2017-03-23
LT3164385T (lt) 2021-10-11
KR102399374B1 (ko) 2022-05-17
PE20170522A1 (es) 2017-05-28
MA40345B1 (fr) 2021-10-29
KR20170023019A (ko) 2017-03-02
ECSP17000222A (es) 2017-02-24
AP2016009643A0 (en) 2016-12-31
EP3164385A1 (en) 2017-05-10
AU2015282909A1 (en) 2017-01-05
EA201692485A1 (ru) 2017-05-31
GEAP202114363A (en) 2021-12-10
SI3164385T1 (sl) 2021-10-29
CL2017000002A1 (es) 2017-06-23

Similar Documents

Publication Publication Date Title
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
HRP20190107T1 (hr) Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens
MY183123A (en) Synthesis of copanlisib and its di hydrochloride salt
MX2016016378A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PH12016501613B1 (en) Pyrazines modulators of gpr6
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201892235A1 (ru) Гранулированная композиция для перорального применения
CY1124594T1 (el) Καινοφανης πολυμορφικη μορφη της υδροχλωρικης ν-[2-(6-φθορο-lη-ινδολ-3-υλ)αιθυλ]-3-(2,2,3,3-τετραφθοροπροποξυ)βενζυλαμινης για την αγωγη της αλτσχαϊμεp
MX2017002609A (es) Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso.
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
UA94667U (uk) Заміщені [2-(3-r-1h-[1,2,4]триазол-5-іл)феніл]аміни, що проявляють гіпоглікемічну активність
IN2014MU00666A (ar)